PRIMARY STUDY

The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease

Key Findings:  While the authors of the study highlight the fact that the precise mechanisms of ECS-based effects (especially those of CB1 and CB2 receptor sites) in the context of treating PD remains to be fully understood, they also expressed their hopes that CB1- and CB2-based agonism or antagonism of may provide hope in suspending the course of PD.

Type of Study:  Meta-analysis

Study Result:  Negative


Cannabinoids Studied:  Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2


Study Location(s):  China

Year of Pub:  2019


Link to study